Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Clinical trial NCT04750928 · RECRUITING

Trial details

NCT number: NCT04750928
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neurofibromatosis 1

Start date: 2021-11-29
Primary completion: 2028-12-31
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.